C
5.47
-0.22 (-3.87%)
| Previous Close | 5.69 |
| Open | 5.75 |
| Volume | 2,885,119 |
| Avg. Volume (3M) | 14,755,291 |
| Market Cap | 269,567,000 |
| Price / Sales | 5.48 |
| Price / Book | 1.09 |
| 52 Weeks Range | |
| Earnings Date | 21 Feb 2024 - 26 Feb 2024 |
| Profit Margin | -259.60% |
| Operating Margin (TTM) | -402.93% |
| Diluted EPS (TTM) | -1.48 |
| Quarterly Revenue Growth (YOY) | 138.20% |
| Total Debt/Equity (MRQ) | 32.99% |
| Current Ratio (MRQ) | 5.70 |
| Operating Cash Flow (TTM) | -80.32 M |
| Levered Free Cash Flow (TTM) | -53.06 M |
| Return on Assets (TTM) | -20.30% |
| Return on Equity (TTM) | -45.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | C4 Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 5.0 |
| Average | 0.00 |
|
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.79% |
| % Held by Institutions | 91.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Guggenheim, 46.25%) | Buy |
| Median | 7.00 (27.97%) | |
| Low | 6.00 (Stephens & Co., 9.69%) | Buy |
| Average | 7.00 (27.97%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 15 Sep 2025 | 6.00 (9.69%) | Buy | 2.66 |
| Guggenheim | 04 Sep 2025 | 8.00 (46.25%) | Buy | 2.67 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration |
| 03 Sep 2025 | Announcement | C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting |
| 07 Aug 2025 | Announcement | C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |